bioAffinity Technologies has prioritized CyPath® Lung as its core commercial focus, aligning resources to accelerate adoption and scale. Growth has been driven by:

  • Expansion of ordering physician sites
  • Increased peer-to-peer education among pulmonologists
  • Integration of CyPath® Lung into clinical workflows for lung cancer risk assessment and nodule management